Lesley J. Burgess

TL;DR: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.

TL;DR: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high- dose atorVastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks.

TL;DR: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotens in-converting enzyme inhibition.

TL;DR: Mipomersen significantly reduced LDL-C, apolipoprotein B, total cholesterol and non-HDL-cholesterol, and lipoprotein(a).

TL;DR: ADA, especially when combined with differential cell counts and lymphocyte/neutrophil ratios, remains a useful test in the diagnosis tuberculous pleuritis.